vs
Side-by-side financial comparison of Applied Therapeutics, Inc. (APLT) and CXApp Inc. (CXAI). Click either name above to swap in a different company.
CXApp Inc. is the larger business by last-quarter revenue ($1.0M vs $1.0M, roughly 1.0× Applied Therapeutics, Inc.). CXApp Inc. runs the higher net margin — -544.1% vs -1899.0%, a 1354.9% gap on every dollar of revenue. On growth, Applied Therapeutics, Inc. posted the faster year-over-year revenue change (719.7% vs -38.5%).
Relief Therapeutics is a Swiss biopharmaceutical company based in Geneva. The company focuses on developing drugs for serious diseases with few or no existing treatment options. Its lead compound, RLF-100, is a synthetic form of a natural peptide that protects the lung. The company was incorporated as Relief Therapeutics Holdings AG (RFLB.S) and listed on the SIX Swiss Exchange in 2016.
CXApp Inc. is a technology firm specializing in digital workplace experience solutions. It offers cloud-based software tools for employee engagement, office space optimization, visitor management, and hybrid work coordination, serving mid-to-large enterprises across North America, APAC and Europe.
APLT vs CXAI — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0M | $1.0M |
| Net Profit | $-19.0M | $-5.6M |
| Gross Margin | — | 86.9% |
| Operating Margin | -1675.8% | -576.9% |
| Net Margin | -1899.0% | -544.1% |
| Revenue YoY | 719.7% | -38.5% |
| Net Profit YoY | 72.3% | -56.7% |
| EPS (diluted) | $-0.13 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $1.0M | ||
| Q3 25 | $1.0M | $1.1M | ||
| Q2 25 | $0 | $1.2M | ||
| Q1 25 | $0 | $1.2M | ||
| Q4 24 | $-1.0K | $1.7M | ||
| Q3 24 | — | $1.9M | ||
| Q2 24 | $144.0K | $1.8M | ||
| Q1 24 | $190.0K | $1.8M |
| Q4 25 | — | $-5.6M | ||
| Q3 25 | $-19.0M | $-3.2M | ||
| Q2 25 | $-21.3M | $-3.1M | ||
| Q1 25 | $-21.8M | $-1.6M | ||
| Q4 24 | $44.0M | $-3.5M | ||
| Q3 24 | — | $-5.4M | ||
| Q2 24 | $2.9M | $-5.3M | ||
| Q1 24 | $-83.9M | $-5.2M |
| Q4 25 | — | 86.9% | ||
| Q3 25 | — | 89.0% | ||
| Q2 25 | — | 86.0% | ||
| Q1 25 | — | 87.7% | ||
| Q4 24 | — | 86.0% | ||
| Q3 24 | — | 80.4% | ||
| Q2 24 | — | 80.0% | ||
| Q1 24 | — | 82.0% |
| Q4 25 | — | -576.9% | ||
| Q3 25 | -1675.8% | -343.4% | ||
| Q2 25 | — | -336.1% | ||
| Q1 25 | — | -306.0% | ||
| Q4 24 | 3302300.0% | -169.7% | ||
| Q3 24 | — | -194.3% | ||
| Q2 24 | -14194.4% | -206.7% | ||
| Q1 24 | -11101.6% | -197.3% |
| Q4 25 | — | -544.1% | ||
| Q3 25 | -1899.0% | -283.4% | ||
| Q2 25 | — | -256.7% | ||
| Q1 25 | — | -132.0% | ||
| Q4 24 | -4400700.0% | -213.6% | ||
| Q3 24 | — | -286.5% | ||
| Q2 24 | 2012.5% | -297.6% | ||
| Q1 24 | -44177.9% | -284.4% |
| Q4 25 | — | — | ||
| Q3 25 | $-0.13 | — | ||
| Q2 25 | $-0.15 | — | ||
| Q1 25 | $-0.15 | — | ||
| Q4 24 | $0.52 | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-0.13 | — | ||
| Q1 24 | $-0.67 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $11.9M | $11.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-561.0K | $14.0M |
| Total Assets | $34.4M | $32.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $11.1M | ||
| Q3 25 | $11.9M | $5.1M | ||
| Q2 25 | $30.4M | $4.9M | ||
| Q1 25 | $50.8M | $3.9M | ||
| Q4 24 | $79.4M | $4.9M | ||
| Q3 24 | — | — | ||
| Q2 24 | $122.2M | — | ||
| Q1 24 | $146.5M | — |
| Q4 25 | — | $14.0M | ||
| Q3 25 | $-561.0K | $15.2M | ||
| Q2 25 | $17.4M | $14.3M | ||
| Q1 25 | $36.7M | $15.6M | ||
| Q4 24 | $57.0M | $15.6M | ||
| Q3 24 | — | $13.6M | ||
| Q2 24 | $72.4M | $16.3M | ||
| Q1 24 | $67.3M | $20.9M |
| Q4 25 | — | $32.4M | ||
| Q3 25 | $34.4M | $28.5M | ||
| Q2 25 | $37.3M | $29.6M | ||
| Q1 25 | $56.9M | $29.3M | ||
| Q4 24 | $86.7M | $31.8M | ||
| Q3 24 | — | — | ||
| Q2 24 | $127.8M | — | ||
| Q1 24 | $151.2M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.4M | $-3.6M |
| Free Cash FlowOCF − Capex | — | $-3.6M |
| FCF MarginFCF / Revenue | — | -355.5% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-10.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-3.6M | ||
| Q3 25 | $-18.4M | $-2.8M | ||
| Q2 25 | $-20.3M | $-3.0M | ||
| Q1 25 | $-28.6M | $-979.0K | ||
| Q4 24 | $-19.5M | $-2.7M | ||
| Q3 24 | — | $-2.1M | ||
| Q2 24 | $-22.6M | $-1.9M | ||
| Q1 24 | $-18.9M | $-650.0K |
| Q4 25 | — | $-3.6M | ||
| Q3 25 | — | $-2.8M | ||
| Q2 25 | — | $-3.0M | ||
| Q1 25 | — | $-984.0K | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-2.1M | ||
| Q2 24 | — | $-1.9M | ||
| Q1 24 | — | $-668.0K |
| Q4 25 | — | -355.5% | ||
| Q3 25 | — | -248.1% | ||
| Q2 25 | — | -247.2% | ||
| Q1 25 | — | -80.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -109.3% | ||
| Q2 24 | — | -108.6% | ||
| Q1 24 | — | -36.7% |
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.4% | ||
| Q2 25 | — | 0.9% | ||
| Q1 25 | — | 0.4% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.2% | ||
| Q2 24 | — | 0.5% | ||
| Q1 24 | — | 1.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -0.44× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -7.80× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
